The sources stated AstraZeneca had requested permission from the Italian authorities to export some 250,000 doses from its Anagni plant, close to Rome.
The Italian authorities refused and the European Fee supported its determination, the sources stated. An EU supply in Brussels stated nationwide authorities had the ultimate say in such issues.
There was no instant remark from AstraZeneca.
The transfer got here simply days after Prime Minister Mario Draghi, who took workplace final month, advised fellow EU leaders that the bloc wanted to hurry up vaccinations and crack down on pharma firms that did not ship on promised provides.
EU international locations began inoculations on the finish of December, however are transferring at a far slower tempo than different nations, together with Israel and ex-EU member Britain. Officers have blamed the gradual progress partly on provide issues with key producers.
AstraZeneca in January minimize its provides to the EU within the first quarter to 40 million doses from 90 million foreseen within the contract, and later advised EU states it will minimize deliveries by one other 50% within the second quarter.
The corporate later stated it was striving to provide lacking doses for the second quarter from outdoors Europe.
Thursday’s ban is believed to be the primary time Europe has prevented vaccine exports to a 3rd nation.
The plant in Anagni is dealing with the ultimate stage of the AstraZeneca manufacturing – the so-called fill and ending of its COVID-19 vaccine.
The positioning is owned by U.S. group Catalent that was anticipated to deal with a whole bunch of tens of millions of AstraZeneca doses over the approaching 12 months.
The Anagni plant can also be anticipated to assist produce the vaccine developed by U.S. drugmaker Johnson & Johnson.